ClinicalTrials.gg
Enrolling by invitationNCT06143202Updated Mar 3, 2026

Feasibility of CGM Use in Hospitalized Youth

An observational study in Hyperglycemia, sponsored by University of Colorado, Denver. Enrolling by invitation at 3 sites in United States. Open to participants aged 2 Years to 26 Years. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by University of Colorado, Denver · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
2 Years to 26 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 316 studies in Hyperglycemia with a site in United States — 29 open to participants now, 38 under way, 1 of them phase 3. Hyperglycemia · United States.

Planned enrollment
22nd of 50
120 · median 84
Started
2025
with 13 others
Observational
51 of 316
7 open now
Primary completion
2027-02
later than 19 of 37 live
Registered
280th of 316
by date

Among the 316 studies in Hyperglycemia with a site in United States, this one is the 22nd largest by planned enrollment of the 50 observational ones that give a count, is one of 14 that started in 2025, is one of 51 observational ones, reaches primary completion later than 19 of the 37 other live ones, and was the 280th registered.

Hyperglycemia

802 studies on the registry are indexed under Hyperglycemia; 115 are open to participants now.

Browse Hyperglycemia studies →

Open to participants now

29 of the 316 studies in Hyperglycemia with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 71 Hyperglycemia studies recruiting now, 42 (59%) set no upper age limit and 23 (32%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 2 Years to 26 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 316 studies in Hyperglycemia with a site in United States, or all of them as a file.
02

Study summary

This study is assessing the feasibility of a continuous glucose monitor during hospital admissions in youth and young adults with hyperglycemia due to diabetes or other underlying conditions that requires frequent glucose monitoring, through patient/family and nursing staff feedback on their perspectives and usability of the system in the hospital will be assessed through surveys. In addition, retrospective glycemic comparisons between CGM data and POC will be conducted.

Read the detailed description

Youth and young adult patients admitted to the hospital for any reason, but require glucose monitoring during the hospitalization will be enrolled in this study. Participant diagnosis can include type 1 diabetes, type 2 diabetes, medication-induced diabetes, cystic fibrosis-related diabetes, or other causes of hyperglycemia that it has been determined by the hospital team requires frequent glucose monitoring, with or without insulin management.

Enrolled participants will wear a blinded continuous glucose monitor for up to 28 days (2 sensors) or until the end of their hospitalization. In addition, enrolled participants will complete a survey to assess their perspectives on the CGM wear experience and interest in future CGM use during hospitalizations. Nursing staff of the enrolled participant will also be invited to complete a survey regarding their perspectives of CGM use in the hospital setting.

03

Conditions studied

  • Hyperglycemia

Keywords

  • Hyperglycemia
  • Continuous glucose monitors
  • Pediatrics
  • Hospital
  • Diabetes
04

Who can participate

Ages eligible
2 Years to 26 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Youth and young adult participants will be admitted to the hospital and have hyperglycemia resulting in an endocrine consult and requiring frequent glucose monitoring.

Nursing staff providing medical care for the youth and young adult participant will be invited to complete a survey on usability of the CGM in the hospital setting.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants will be 2 to less than 26 years of age at the time of enrollment.
  2. Participants will have a diagnosis of type 1 diabetes, type 2 diabetes, diabetes/hyperglycemia due to an underlying condition (such as in cystic fibrosis, monogenic diabetes), or medication induced diabetes/hyperglycemia (such as -induced hyperglycemia or PEG-asparaginase induced hyperglycemia) and would benefit clinically from close glucose monitoring during hospitalization due to fluctuations in blood glucose values.
  3. Participant is expected to be in the hospital for longer than 12 hours after study enrollment with a goal of 36 hours or more as determined by study investigator or trained staff.
  4. Participant is willing to wear the continuous glucose monitor for the duration of the hospital admission or the lifespan of a continuous glucose monitor (7-14 days).

Exclusion criteria

Exclusion Criteria:

  1. Has had a history of a significant skin reaction to the adhesives of a continuous glucose monitor in the past or concerns that one may occur due to underlying skin conditions (ie severe eczema, uncontrolled psoriasis, etc).
  2. Planned MRI or surgery during the study device use (can be enrolled pre or post procedure if sufficient time for sensor wear as determined by investigator [i.e. 24-48 before planned procedure]).
  3. Admission to inpatient psychiatry.
  4. Pregnancy.
  5. Currently using hydroxyurea.
  6. A condition that the investigator determines would prevent the patient from participation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • You and young adult patients with hyperglycemia

    Any youth and young adult patient admitted to the hospital and requiring an endocrine consult for frequent glucose monitoring and hyperglycemia management

    Device: Freestyle Libre 3 Continuous Glucose Monitor

  • Nursing staff

    Nursing staff providing medical care for youth and young adult patients enrolled in the study.

Interventions

  • DeviceFreestyle Libre 3 Continuous Glucose Monitor

    Youth and young adult participants will wear a blinded Freestyle Libre 3 CGM. Data will not be available, and therefore the device will not be used to modify medical management.

06

What researchers measure

Primary outcomes

  1. Retrospective glycemic CGM and point of care comparison

    Glycemic data related to time in range, time hypoglycemic, time hyperglycemic and the time of first onset of hypoglycemia and hyperglycemia will be obtained by both CGM and point of care glucose values.

    Time frame: Duration of study, approximately 1 year from study start

Secondary outcomes

  1. Nursing staff perspectives of CGM use in the hospital

    Surveys will be provided to the nursing staff associated with an enrolled patient participant to obtain qualitative perspectives on the usability of CGMs in the hospital setting

    Time frame: Duration of study, approximately to 1 year from study start

  2. Patient/Family perspectives of CGM use in the hospital

    Surveys will be completed by patients/family to evaluate their experience with sensor wear in the hospital, sensor insertion, and goals for glycemic monitoring while in the hospital.

    Time frame: Duration of study, approximately 1 year from study start

  3. Feasibility of CGM use through assessment of discontinuation and data loss

    Identify the frequency and causes of sensor discontinuation as well as information on sensor data loss.

    Time frame: Duration of study, approximately 1 year from study start

  4. Health economics data

    Pilot analysis of health economics data from costs related to glycemic monitoring during the hospitalization.

    Time frame: Duration of study, approximately 1 year from study start

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Feb 2027, 18 months after the start.

Of 63 non-industry observational studies under Hyperglycemia, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's planned 18 months is below that.

Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2023
First posted
Nov 22, 2023
StartActual
Jul 15, 2025
Primary completionEst.
Feb 14, 2027
CompletionEst.
Feb 14, 2027
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06143202
Responsible party
Sponsor
First posted
Nov 22, 2023
Start date
Jul 15, 2025
Primary completion
Feb 14, 2027 (estimated)
Completion
Feb 14, 2027 (estimated)
Last update
Mar 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion